[Federal Register Volume 64, Number 116 (Thursday, June 17, 1999)]
[Notices]
[Page 32508]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 99-15401]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration


Antiviral Drugs Advisory Committee; Notice of Meeting

AGENCY:  Food and Drug Administration, HHS.

ACTION:  Notice.

-----------------------------------------------------------------------

    This notice announces a forthcoming meeting of a public advisory 
committee of the Food and Drug Administration (FDA). At least one 
portion of the meeting will be closed to the public.
    Name of Committee: Antiviral Drugs Advisory Committee.
    General Function of the Committee: To provide advice and 
recommendations to the agency on FDA's regulatory issues.
    Date and Time: The meeting will be held on July 29, 1999, 8:30 a.m. 
to 5 p.m.
    Location: Holiday Inn, Goshen Room, Two Montgomery Village Ave., 
Gaithersburg, MD.
    Contact Person: Rhonda W. Stover or John B. Schupp, Center for Drug 
Evaluation and Research (HFD-21), Food and Drug Administration, 5600 
Fishers Lane, Rockville, MD 20857, 301-827-7001, or FDA Advisory 
Committee Information Line, 1-800-741-8138 (301-443-0572 in the 
Washington, DC area), code 12531. Please call the Information Line for 
up-to-date information on this meeting.
    Agenda: The committee will review and discuss trade secret and/or 
confidential information relevant to pending investigational new drug 
applications (IND's) and drug development plans.
    Procedure: On July 29, 1999, from 8:30 a.m. to 9:30 a.m., the 
meeting is open to the public. Interested persons may present data, 
information, or views, orally or in writing, on issues pending before 
the committee. Written submissions may be made to the contact person by 
July 22, 1999. Oral presentations from the public will be scheduled 
between approximately 8:30 a.m. and 9:30 a.m. Time allotted for each 
presentation may be limited. Those desiring to make formal oral 
presentations should notify the contact person before July 22, 1999, 
and submit a brief statement of the general nature of the evidence or 
arguments they wish to present, the names and addresses of proposed 
participants, and an indication of the approximate time requested to 
make their presentation.
    Closed Committee Deliberations: On July 29, 1999, from 9:30 a.m. to 
5 p.m., the meeting will be closed to permit discussion and review of 
trade secret and/or confidential information relevant to pending IND's 
and drug development plans. This portion of the meeting will be closed 
to permit discussion of this information (5 U.S.C. 552b(c)(4)).
    Notice of this meeting is given under the Federal Advisory 
Committee Act (5 U.S.C. app. 2).

    Dated: June 10, 1999.
Michael A. Friedman,
Deputy Commissioner for Operations.
[FR Doc. 99-15401 Filed 6-16-99; 8:45 am]
BILLING CODE 4160-01-F